Skip to content
CompoundSci
All peptides
Research vial labelled Tesamorelin, a Growth hormone secretagogue peptide studied in preclinical and clinical literature

Tesamorelin

An approved GHRH analog studied for visceral fat reduction in HIV-associated lipodystrophy.

One of the few peptides here with FDA-reviewed randomised trial data.

General profile

Class
Growth hormone secretagogue
Evidence
Strong human evidence
Studied dose range
1–2 mg
Frequency in protocols
Daily in trial protocols
Route
Subcutaneous
Half life
~26 minutes (pulse outlasts plasma)
Reconstitution
2 mL bacteriostatic water per 10 mg vial
Storage
Refrigerated, ~28 days

Timing and cycling in the literature

Usually dosed in the bedtime window, fasted

Daily in trial protocols

Works on the growth-hormone axis, which pulses during early slow-wave sleep. Food, especially carbohydrate, blunts that pulse, so protocols use a fasted window at least two hours after eating.

Reported cycle: 12 weeks on, 4 weeks off

The registration trials ran 26 weeks with visceral fat measured at 12 and 26 weeks. This is one of the few compounds here with a real long duration dataset.

Watch for: Fasting glucose and HbA1c, joint aches, swelling in the hands, and carpal tunnel symptoms.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopTiming

    Tesamorelin + CJC-1295 + Ipamorelin

    Do not run on the same day

    Both drive the same growth-hormone axis. Stacking them does not double the pulse, it flattens it: continuous stimulation of GHRH and ghrelin receptors promotes desensitisation, and the reported side effect load (water retention, carpal tunnel symptoms, insulin resistance) rises with total exposure. Pick one.

  • Hard stopTiming

    Tesamorelin + Sermorelin

    Two GHRH analogs on the same axis

    Both are growth-hormone releasing hormone analogs hitting the same receptor. Running them together raises total exposure without raising the pulse, and desensitisation plus water retention follow.

  • Hard stopTiming

    Tesamorelin + CJC-1295 with DAC

    Do not stack GHRH analogs

    Same axis, and the DAC version is still circulating days later. Any additional GHRH analog lands on top of a level that has not cleared.

  • Separate syringesTiming

    Tesamorelin + GLP-1 analogs

    Do not start in the same week

    GLP-1 agonists slow gastric emptying and change glucose handling, while growth-hormone axis compounds push glucose the other way. Introducing both at once makes glycaemic changes unreadable and, in the trial literature, is where the insulin-resistance signal shows up.

  • Pick oneRedundant, pick one

    Tesamorelin + CJC-1295 with DAC

    Same target hit twice

    Both sit on the GHRH pathway. More water retention risk, not more useful GH signal.

  • Pick oneRedundant, pick one

    Tesamorelin + CJC-1295 without DAC

    Same target hit twice

    Same GHRH lane. Pick the arm you want and titrate it.

  • Pick oneRedundant, pick one

    Tesamorelin + Sermorelin

    Same target hit twice

    Same GHRH lane, different half-lives. Running both does not compound the pulse.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how Tesamorelin fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: Registrational randomised trials with imaging endpoints.

Open questions: Insulin resistance signals appear with exposure, and use outside the approved population is off-label.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature